Introduction
============

Cardiovascular disease is the serious cause of mortality in developed and developing countries.[@b1-ARYA-09-311] This disease is also the major cause of morbidity, mortality, and disability in Iranian people and accounts for nearly 50% of mortality each year.[@b2-ARYA-09-311] Recent research has found atherosclerosis to be a chronic inflammation that leads to an acute clinical event by plaque rupture.[@b3-ARYA-09-311] Inflammation appears by different stimuli, such as oxidative stress. Oxidative metabolites can activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and increase induction of proinflammatory cytokines.[@b4-ARYA-09-311]-[@b6-ARYA-09-311] NF-κB is a group of transcription factors that regulate the inflammatory and immune response.[@b7-ARYA-09-311] inflammation and oxidative stress are crucial in the atherosclerosis process.[@b8-ARYA-09-311]

The anti-inflammatory and antioxidant effect of nutrients may improve cardiovascular disease.[@b7-ARYA-09-311],[@b8-ARYA-09-311] Today, there is a widespread interest in the health beneficial properties of conjugated linoleic acids (CLA) and ω-3 fatty acids.[@b9-ARYA-09-311] CLA was found naturally in food from ruminant animals such as dairy and meat products.[@b10-ARYA-09-311] For nearly a decade, the health benefits of CLA have been investigated in animal models. It has been observed that animals fed an atherogenic diet and supplemented with CLA had significantly less aortic lesions.[@b11-ARYA-09-311],[@b12-ARYA-09-311] Nagao and Yanagita have also found 30% regression of atherosclerotic lesions in CLA supplemented rabbits.[@b11-ARYA-09-311] ω-3 fatty acids are essential fatty acids that the human body needs for metabolic function.[@b13-ARYA-09-311] There are considerable evidence from randomized controlled trials (RCTs) indicating that ω-3 fatty acids from fish and fish oil are protective against atherosclerosis.[@b14-ARYA-09-311] Some studies attributed these prospective properties of omega-3 fatty acids on atherosclerosis to its anti-inflammatory effect.[@b15-ARYA-09-311],[@b16-ARYA-09-311] To the best of our knowledge, this paper was the first human study which assessed the effect of CLA supplementation on atherosclerosis patients. Due to high prevalence of atherosclerosis in the Iranian population, this study was carried out to evaluate the effect of omega-3 fatty acids and CLA on inflammatory and oxidative stress markers in atherosclerotic patients.

Materials and Methods
=====================

This was a 2-month clinical randomized trial. To determine the sample based on power = 80% and α = 0.05, the results of the study of Omrani et al. was used.[@b17-ARYA-09-311] The sample size in each group was calculated as 30. Therefore, 90 atherosclerotic patients (40 males and 50 females) aged 30 to 60 years with angiographically diagnosed coronary atherosclerosis who were referred to Emam Reza Heart Clinic from February to March 2011 were recruited for this study. Volunteers had the following criteria: history of angina, myocardial infarction or bypass surgery, body mass index (BMI) of 18.5-24.9 kg/m2, no pregnancy, and no dietary supplements. Volunteers with acute heart failure, acute arrhythmia, or chronic inflammatory disease were excluded from the study. Most of the patients consumed lipid lowering drugs; thus, the dosage and type of these drugs were kept consistent. Participants followed their regular diet and physical activity during the study. To determine the food intake and macro- and micronutrient consumptions of participants, the food frequency questionnaire (FFQ) was completed for each patient at the beginning of the study.

The study was approved by the Research Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran. All participants gave a written informed consent. The volunteers were randomly divided into 3 groups using balanced block randomization (BBR) protocol. They were allocated to receive 3 g/d CLA (3 × 1 g soft gel, a 50:50 isomer blend of cis-9 trans-11 and trans-10 cis-12), 1920 mg/d omega-3 fatty acids (3 × 640 mg soft gel blend of 210 mg DHA and 310 mg EPA), and the placebo.

CLA soft gel was obtained from Puritan\'s Pride (USA) and omega-3 fatty acids soft gel was produced by Seven Seas Ltd (UK). Placebo (olive oil) was produced by Zahravi Pharmaceutical Company (Tehran, Iran). Each group was invited separately to take their supplements every two weeks and the researcher supervised ingestion of supplements every week.

**Procedure**

Blood sampling: Fasting blood samples (5 cc) were collected at the beginning and the end of the study and immediately centrifuged (3000 × g, 10 min, 4ºC); then, the plasma was placed into a tube and stored at -70oC until analysis for high sensitivity C-reactive protein (hs-CRP), IL-6, malondialdehyde (MDA), and glutathione peroxidase (GPx).

Anthropometric assessment: Body weight was measured by Seca 713 scale while the subjects were minimally clothed and their height was determined using measuring tape without shoes. Then, BMI \[weight (kg) / hight2 (m)\] was calculated.

Biochemical analysis: Hs-CRP measurement was done by a highly sensitive enzyme-linked immunosorbent assay kit (IBL, Minnesota, USA), and IL-6 assay was performed by radioimmunoassay kit (IRMA source, Belgium, Louvain-la-Neuve). GPx enzyme activity was measured by the coupled enzyme assay commercial kit (Cayman, Michigan, USA). GPx catalyzes the oxidation of glutathione (GSH) by cumene hydroperoxide, in the presence of glutathione reductase (GR) and Nicotinamide adenine dinucleotide phosphate (NADPH); oxidized glutathione (GSSG) is immediately converted into the reduced form with concomitant oxidation of NADPH to NADP+. Decrease in absorbance at 340 nm is measured.[@b18-ARYA-09-311] MDA was determined using the thiobarbituric acid (TBA) method.

**Statistical analysis**

Data were analyzed using SPSS for Windows (version 19; SPSS Inc., Chicago, IL, USA). Normality of the data was evaluated by the Kolmogorov-Smirnov test. Normality distributed data were expressed as mean ± standard deviation. Paired t-test was used for within-group effects from baseline. Differences between groups from baseline to 8 weeks were assessed using ANOVA followed by a post-hoc Dunnett analysis. FFQ was analyzed using Food Processor Nut4 software. P values \< 0.05 were considered statistically significant.

Results
=======

As shown in [figure 1](#f1-ARYA-09-311){ref-type="fig"} three patients were excluded during the study and finally data from 87 patients (39 men and 48 women) were collected and analyzed and with on average over 95% of supplements being apparently consumed by trial participants. Moreover, there were no significant differences in terms of dosage and type of lipid lowering drugs between the groups. As shown in [tables 1](#t1-ARYA-09-311){ref-type="table"} and [2](#t2-ARYA-09-311){ref-type="table"}, age, weight, height, body mass index, disease duration, and biochemical markers did not differ significantly between the groups. Concerning differences in food intake between patients, analysis of food frequency questionnaire showed no differences in food intake between the patients (results will be presented in a separate article). At the end of the study, CRP differed significantly in CLA group as compared to baseline. However, this was not the case with IL-6, although a decreasing trend was seen in IL-6 status (16.1 ± 10.2 vs 12.9 ± 8.1). ω-3 supplementation reduced both CRP and IL-6 significantly during the study compared to baseline ([Table 3](#t3-ARYA-09-311){ref-type="table"}).

In both CLA and omega-3 groups, MDA and GPx reduced significantly as compared to the baseline ([Table 2](#t2-ARYA-09-311){ref-type="table"}). As shown in [table 4](#t4-ARYA-09-311){ref-type="table"}, there were no significant changes in mean differences of MDA and GPx between the groups. Although hs-CRP and IL-6 differed significantly in the ù-3 group relative to the placebo group, there was no significant change in mean differences of hs-CRP and IL-6 in CLA groups in comparison to the placebo ([Table 4](#t4-ARYA-09-311){ref-type="table"}).

Discussion
==========

The present study determined the effect of CLA and omega-3 fatty acid supplementation on some key atherosclerosis risk factors in a group of atherosclerosis patients. Considering the association between inflammation and atherosclerosis, we evaluated several plasma markers of inflammation, such as hs-CRP, as potential tools for prediction of the risk of coronary disease.[@b19-ARYA-09-311] Evidence indicated that oxidative stress may cause pro-inflammatory effects.[@b20-ARYA-09-311],[@b21-ARYA-09-311] Some reports demonstrated that oxidative stress is necessary for NF-κB pathway.[@b5-ARYA-09-311] Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors whose activation suppresses the production of pro-inflammatory cytokines by inhibiting NF-κB pathway.[@b5-ARYA-09-311] CLA and ù-3 fatty acids increase the peroxisome proliferator-activated receptor (PPAR).[@b20-ARYA-09-311],[@b21-ARYA-09-311]

A few studies have investigated the effect of CLA isomers on inflammation in the human population. As a report by Steck et al. showed, CLA isomers increase the CRP level.[@b22-ARYA-09-311] However, t10,c12 CLA (albeit at a high dose) had more significant effects on increased CRP in recent studies.[@b23-ARYA-09-311] Raff et al. reported the non-significant effect of CLA supplementation on CRP concentration.[@b24-ARYA-09-311] In the present study, supplementation with CLA for 2 months reduced the hs-CRP level in this group during the study. The dose of t10,c12 CLA used in this study (1.27 g/d for 8 weeks) was lower than that used in the studies by Steck et al.[@b22-ARYA-09-311] (3.2 g/d for 12 weeks) and Raff et al.[@b24-ARYA-09-311] (2.1 g/d for 5 weeks), which may account for the effect of CLA on CRP in our study. As reported by LaRosa et al. t10,c12 CLA supplementation increases IL-6 level in rats.[@b25-ARYA-09-311] Although, in the current study, CLA had no effect on IL-6, which is consistent with the study of Raff et al.[@b24-ARYA-09-311]

Our data suggest that supplementation with ω-3 decreases hs-CRP and IL-6 measurement. A similar result was gained by Rallidis et al. who reported that 3 months of ل-linolenic acid supplementation in dyslipidaemic patients decreases CRP and IL-6 levels.[@b26-ARYA-09-311] In a study by Chan et al. 6 weeks of ω-3 supplementation did not cause any significant change in CRP levels.[@b27-ARYA-09-311] Several studies indicated that ω-3 fatty acid anti-inflammatory effect may result from activation of PPAR-γ. This fatty acid also directly decreases the inflammatory cytokine production. However, the mechanism is unclear.[@b28-ARYA-09-311]

Extensive evidence from studies in animal models and data from human studies have indicated the role of oxidative stress in cardiovascular disease. In this study, we showed the significant effect of CLA and ω-3 on oxidative stress. CLA and ω-3 increase the levels of GSH with over-expression of gamma-glutamylcysteine ligase which was accepted as an antioxidant response.[@b29-ARYA-09-311] In the study of Choi et al. CLA supplementation increased GPx activity.[@b30-ARYA-09-311] Glutathione peroxidase (GPx) is an antioxidant enzyme that reduces hydrogen peroxide by reduced glutathione.[@b31-ARYA-09-311]

On the other hand, the study by Taylor et al. demonstrated that CLA increase oxidative stress.[@b23-ARYA-09-311] There is conflicting evidence about the effects of CLA supplementation on oxidative stress. According to a previous study, CLA increases the oxidative stability of the liver which suggests CLA supplementation enhances the protection to oxidative stress.[@b32-ARYA-09-311] Park et al. indicated that CLA supplementation reduces oxidative stress in mice.[@b32-ARYA-09-311]

Other studies have shown that supplementation with ω-3 fatty acids slows the progression of oxidative stress.[@b33-ARYA-09-311] As reported by Tayyebi-Khosroshahi et al. ω-3 fatty acids increase the level of glutathione peroxidase and decrease the level of MDA in hemodialysis patients.[@b33-ARYA-09-311] In the study by Bhattacharya et al. ω-3 supplementation increased GPx activity.[@b34-ARYA-09-311] In another study by Iraz et al. ω-3 supplementation decreased MDA levels.[@b35-ARYA-09-311] However, the study by Oarada et al. has revealed increased lipid peroxidation due to ω-3 supplementation in mice.[@b36-ARYA-09-311] Shidfar et al. in their study, suggest that these contradictory results of plasma MDA and lipid peroxidation with ù-3 supplementation may be due to the level of antioxidants in the plasma or supplement content to suppress free radical production, differences in the population of studies, and the duration of the study.[@b37-ARYA-09-311]

Conclusion
----------

In conclusion, this study showed the beneficial properties of CLA and the many more of ω-3 fatty acids on inflammatory and oxidative stress markers in atherosclerosis. However, more research, particularly on CLA supplementation, is necessary in order to give definite comments in this regard.

To determine the food intake of participants the FFQ was completed for each patient at the beginning of the study. However, the limitation of this study was that we did not assess dietary intake and physical activity during the study, although the randomized design should have clearly lowered the risk of such bias, and all subjects were instructed to maintain their usual lifestyle habits. On the other hand, patients had normal BMI, so this might have affected our results.
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###### 

Baseline characteristics of the study population

                                           Control group (n = 28)[\*](#tfn2-ARYA-09-311){ref-type="table-fn"}   CLA group (n = 29)   Omega-3 group (n = 30)   P[\*\*\*](#tfn4-ARYA-09-311){ref-type="table-fn"}
  ---------------------------------------- -------------------------------------------------------------------- -------------------- ------------------------ ---------------------------------------------------
  Age (year)                               55.85 ± 14.13[\*\*](#tfn3-ARYA-09-311){ref-type="table-fn"}          52.79 ± 14.11        54.53 ± 15.21            0.29
  Weight (kg)                              68.21 ± 7.82                                                         67.06 ± 8.01         67.66 ± 7.96             0.89
  Height (cm)                              166.21 ± 5.75                                                        167.51 ± 9.57        166.80 ± 6.33            0.48
  BMI (kg/m^2^)                            24.66 ± 2.34                                                         24.02 ± 2.76         24.30 ± 2.34             0.68
  Cardiovascular disease duration (year)   3.89 ± 2.00                                                          3.50 ± 2.05          4.10 ± 1.96              0.56

CLA: Conjugated linoleic acids; BMI: Body mass index;

N refers to the number of participants in each group

All values are mean ± SD

Significance was determined using one-way ANOVA

###### 

Baseline biochemical markers of the study population

                      Control group (n = 28)[\*](#tfn6-ARYA-09-311){ref-type="table-fn"}   CLA group (n = 29)   Omega-3 group (n = 30)   P[\*\*\*](#tfn8-ARYA-09-311){ref-type="table-fn"}
  ------------------- -------------------------------------------------------------------- -------------------- ------------------------ ---------------------------------------------------
  hs-CRP (mg/l)       5.08 ± 5.02[\*\*](#tfn7-ARYA-09-311){ref-type="table-fn"}            7.48 ± 5.64          4.43 ± 4.13              0.05
  IL-6 (pg/ml)        12.88 ± 9.13                                                         16.13 ± 10.21        18.59 ± 11.12            0.11
  MDA (mol/l)         4.46 ± 2.52                                                          3.7 ± 1.77           3.98 ± 1.50              0.37
  GPx (nmol/ml/min)   172.06 ± 55.84                                                       125 ± 46.06          144.57 ± 56.89           0.07

CLA: Conjugated linoleic acids; Hs-CRP: High-sensitivity C-reactive protein; IL-6: Interleukin-6; MDA: Malondialdehyde; GPx: Glutathione peroxidase

N refers to the number of participants in each group;

All values are mean ± SD

Significance was determined using one-way ANOVA

###### 

Effect of supplementation on biochemical indices at the end of the study

  Indices             Control group (n = 28)[\*](#tfn10-ARYA-09-311){ref-type="table-fn"}   CLA group (n = 29)   Omega-3 group (n = 30)                                                                            
  ------------------- --------------------------------------------------------------------- -------------------- ------------------------ --------------- --------------- ---------- -------------- -------------- -------
  Hs-CRP (mg/l)       5.08 ± 5.02[\*\*](#tfn11-ARYA-09-311){ref-type="table-fn"}            5.03 ± 4.46          0.90                     7.48 ± 5.64     5.95 ± 5.87     0.010      4.43±4.13      1.60±1.41      0.010
  IL-6 (pg/ml)        12.88 ± 9.13                                                          13.51 ± 8.86         0.70                     16.13 ± 10.21   12.95 ± 8.10    0.060      18.59±11.12    13.37±9.44     0.040
  MDA (mol/l)         4.46 ± 2.52                                                           3.64 ± 1.32          0.09                     3.7 ± 1.77      2.4 ± 0.80      \< 0.001   3.98±1.50      2.87±1.55      0.001
  GPx (nmol/ml/min)   172.06 ± 55.84                                                        194.13 ± 105.42      0.14                     125 ± 46.06     171.4 ± 68.90   \< 0.001   144.57±56.89   174.61±62.80   0.001
  BMI (kg/m^2^)       24.66 ± 2.34                                                          24.70 ± 2.26         0.31                     24.02 ± 2.76    23.98 ± 2.78    0.370      24.30±2.34     24.40±2.34     0.450

CLA: Conjugated linoleic acids; Hs-CRP: High-sensitivity C-reactive protein; IL-6: Interleukin-6; MDA: Malondialdehyde; GPx: Glutathione peroxidase; BMI: Body mass index

N refers to number of participant in each group

Values are mean ± SD

Significance was determined using paired t-test

###### 

Mean differences[†](#tfn14-ARYA-09-311){ref-type="table-fn"} and changes in biochemical indices

                      Control group (n = 28)[\*](#tfn15-ARYA-09-311){ref-type="table-fn"}   CLA group (n = 29)   Omega-3 group (n = 30)   P                                                                              
  ------------------- --------------------------------------------------------------------- -------------------- ------------------------ -------- ------------------------------------------------------------ -------- ------
  hs-CRP (mg/l)       -0.05 ± 0.78[\*\*\*](#tfn17-ARYA-09-311){ref-type="table-fn"}         -0.98                -1.52 ± 0.77             -20.00   -2.80^[‡](#tfn18-ARYA-09-311){ref-type="table-fn"}^ ± 0.76   -63.88   0.04
  IL-6 (pg/ml)        0.62 ± 1.66                                                           4.89                 -3.17 ± 1.63             -19.71   -5.18 ± 1.60                                                 -28.07   0.41
  MDA (mol/l)         -0.81 ± 0.36                                                          -18.16               -1.30 ± 0.36             -35.13   -1.10 ± 0.35                                                 -27.88   0.62
  GPx (nmol/ml/min)   22.07 ± 12.76                                                         12.82                45.45 ± 12.54            36.80    30.04 ± 12.33                                                20.77    0.41

CLA: Conjugated linoleic acids; Hs-CRP: High-sensitivity C-reactive protein; IL-6: Interleukin-6; MDA: Malondialdehyde; GPx: Glutathione peroxidase

Difference between values after and before the study

N refers to number of participant in each group

The percent of changes in biochemical before and after study

Values are mean ± SD

Significance was determined using ANOVA
